Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Shaad Essa Abdullah"'
Autor:
Ryan J. Sullivan, Mohammed M. Milhem, Lev V. Demidov, Karl D. Lewis, Max Schlaak, Sophie Piperno-Neumann, Shaad Essa Abdullah, Claire Watkins, Howard Goodall, John M. Kirkwood
Publikováno v:
Journal of Clinical Oncology. 40:9585-9585
9585 Background: Tebentafusp (tebe) is the first T cell receptor therapeutic to demonstrate overall survival (OS) benefit in a randomized Phase 3 study vs investigator’s choice (IC) [ NCT03070392 ]. OS benefit was also observed in patients (pts) wi
Autor:
Mark R. Middleton, Omid Hamid, Alexander Noor Shoushtari, Friedegund Elke Meier, Todd Michael Bauer, April K.S. Salama, John M. Kirkwood, Paolo Antonio Ascierto, Paul Lorigan, Cornelia Mauch, Marlana M. Orloff, T.R. Jeffry Evans, Shaad Essa Abdullah, Yuan Yuan, James Mitchell, Jessica Cecile Hassel
Publikováno v:
Journal of Clinical Oncology. 40:104-104
104 Background: Tebe is a T-cell receptor bispecific (gp100 x CD3) against gp100 peptide-HLA-A2 complexes that are overexpressed in uveal (UM)/cutaneous melanoma (CM). Tebe is the only therapy to show an OS benefit (HR 0.51) in a phase (Ph) 3 trial i
Autor:
Alexandra Ikeguchi, Joseph J. Sacco, Jason J. Luke, T.R. Jeffry Evans, Brendan D. Curti, Kevin B. Kim, Shaad Essa Abdullah, Claire Watkins, Ozgur Karakuzu, Paul D. Nathan
Publikováno v:
Journal of Clinical Oncology. 40:9584-9584
9584 Background: All immune therapies that rapidly activate T cells, including T cell engagers, can induce cytokine release syndrome (CRS). Tebentafusp (tebe), a T cell receptor bispecific (gp100 x CD3) can also induce skin adverse events (AEs), due
Autor:
Serge Leyvraz, Takami Sato, Leonel Hernandez-Aya, Omid Hamid, Sarah Lockwood, Enrique Espinosa, Patricia Mendez, Joseph J. Sacco, Jessica C. Hassel, Marcus O. Butler, Jason J. Luke, Richard D. Carvajal, Daniel Sum, Paul C. Nathan, Matthew J. Rioth, Douglas B. Johnson, Shaad Essa Abdullah, Alexander N. Shoushtari, Alexandra Ikeguchi, Josep M. Piulats
Publikováno v:
Journal of Clinical Oncology. 39:e21513-e21513
e21513 Background: Tebe is a bispecific gp100-targeted T cell receptor fusion protein that can redirect polyclonal T cells to target gp100+ cells leading to T cell activation and release of inflammatory mediators. Hepatocytes do not express gp100 and
Autor:
Anthony M. Joshua, Jessica C. Hassel, John M. Kirkwood, Sophie Piperno-Neumann, Christopher J. Holland, Richard D. Carvajal, Sebastian Ochsenreither, Alexander N. Shoushtari, Omid Hamid, Max Schlaak, Shaad Essa Abdullah, Jean-François Baurain, Reinhard Dummer, Ryan J. Sullivan, Marcus O. Butler, Howard Goodall, Piotr Rutkowski, Paul C. Nathan, Marlana Orloff, Joseph J. Sacco
Publikováno v:
Journal of Clinical Oncology. 39:9527-9527
9527 Background: Tebe is a bispecific consisting of an affinity-enhanced T cell receptor fused to an anti-CD3 effector that can redirect T cells to target gp100+ cells. In this Phase (Ph) 3, randomized trial of first line (1L) metastatic uveal melano
Autor:
John M. Kirkwood, Ryan J. Sullivan, Jessica C. Hassel, Shaad Essa Abdullah, Piotr Rutkowski, Sophie Piperno-Neumann, Joseph J. Sacco, Max Schlaak, Marcus O. Butler, Josep M. Piulats, Sebastian Ochsenreither, Jean-François Baurain, Anthony M. Joshua, Paul C. Nathan, Reinhard Dummer, Sarah Lockwood, Alexander N. Shoushtari, Marlana Orloff, Mughda Deo
Publikováno v:
Journal of Clinical Oncology. 39:9509-9509
9509 Background: Tebentafusp (tebe) is the first T cell receptor (TCR) therapeutic to demonstrate an overall survival (OS) benefit in a randomized Phase 3 (Ph3) study [ NCT03070392 ]. In Ph2, 42% of pts with best overall response (BOR) of progressive
Autor:
Marcus O. Butler, Marlana Orloff, Claire Watkins, Howard Goodall, Alexander N. Shoushtari, Joseph J. Sacco, Richard D. Carvajal, Max Schlaak, Shaad Essa Abdullah
Publikováno v:
Journal of Clinical Oncology. 39:9526-9526
9526 Background: Tebentafusp (tebe) is a bispecific consisting of an affinity-enhanced T cell receptor fused to an anti-CD3 effector that can redirect T cells to target gp100+ cells. Tebe significantly improved OS compared to investigator’s choice
Autor:
Josep M. Piulats, Alexandra Ikeguchi, Omid Hamid, Richard D. Carvajal, Jessica C. Hassel, Takami Sato, Laura C. Collins, Shaad Essa Abdullah, Serge Leyvraz, Jason J. Luke, Joseph J. Sacco, Alexander N. Shoushtari, Michelle L. McCully, Douglas B. Johnson, Marcus O. Butler, Enrique Espinosa, Leonel Hernandez-Aya, Sarah Lockwood, Paul C. Nathan, Matthew J. Rioth
Publikováno v:
Journal of Clinical Oncology. 39:9531-9531
9531 Background: Cytokine-mediated adverse events (AEs) are commonly reported in pts treated with T cell engaging therapies. Tebentafusp (tebe), a bispecific consisting of an affinity-enhanced T cell receptor fused to an anti-CD3 effector that can re
Autor:
Brandon W. Higgs, Koustubh Ranade, Mohammed M. Dar, Chen Gao, Shaad Essa Abdullah, Chris Morehouse
Publikováno v:
Journal of Clinical Oncology. 37:2563-2563
2563 Background: Treatment with ICIs can manifest immune-related adverse events (irAEs), which have correlated with clinical outcomes in certain tumors. However, timing of these events and how early irAEs correlate with outcomes is unclear. We assess
Autor:
Shaad Essa Abdullah, Phillip A. Dennis, Chen Gao, Jamie E. Chaft, Matthew D. Hellmann, Brandon W. Higgs, Qu Zhang, Neil H. Segal
Publikováno v:
Journal of Clinical Oncology. 37:2546-2546
2546 Background: Early on-treatment changes in ctDNA may identify responders to immunotherapy and complement radiologic assessment of benefit. Here we investigate how early changes in ctDNA associate with long-term survival following treatment with i